Findings from a postmarketing observational study showed an increased risk of GBS during the 42 days following vaccination.

The FDA is adding a warning about Guillain-Barré syndrome to the respiratory syncytial virus vaccines manufactured by GSK and ...

A post-marketing review by the FDA detected an increased risk of the autoimmune condition in patients inoculated with GSK’s ...

Before the RSV vaccines were approved, the FDA flagged potential GBS risks with the vaccines. After approval, the CDC ...

The change was prompted by postmarketing observational studies that suggest an increased risk of GBS within 42 days of ...

Barré syndrome, although it said data don’t prove a causal link and affirmed the shots’ benefit outweighs their risks.

On the other hand, if the FDA rejects Annexon's filing, Annexon may have to go back and revise its RWE study or even open a ...

Guillain-Barré syndrome (GBS) is an acute inflammatory neuropathy that can lead to severe weakness of the limbs, face, and respiratory muscles. Its pathophysiology involves autoantibodies that ...

Regulators say, however, the benefits of vaccination with Abrysvo and Arexvy in preventing respiratory syncytial virus ...

Members of Class 130 in the practical nursing program at the Wilkes-Barre Area Career and Technical Center received their practical nursing diplomas on Nov. 15. The commencement ceremony was held ...

In the early 1950s there were four vaccines routinely used in the United States: diphtheria, tetanus, pertussis, and smallpox. Three of these vaccines (diphtheria, tetanus, and pertussis) were ...